Request more information or explore ordering options to bring Precise Tumor testing to your practice.
Request informationBack
By submitting your personal information, you agree to be contacted with newsletters, marketing or promotional materials, and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in the communication we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Notice.
Contact Information
Whether you’ve heard about genetic testing before or want to learn more, we can help provide in-depth information on the test and your testing options.
Precise Tumor simplifies patient care for clinicians by providing straightforward interpretations, prioritization of therapies, and the next steps specific to each patient’s tumor genomic results.
Precise Tumor is a next generation sequencing assay that analyzes more than 500 cancer-related genes, as well as key immuno-oncology biomarkers such as microsatellite instability (MSI) and tumor mutational burden (TMB), with broad coverage of guidelines.1
Precise Tumor identifies clinically relevant DNA and RNA variants to help guide personalized treatment decisions. By focusing on key guideline-recommended biomarkers and emerging pan-cancer targets, Precise Tumor enables comprehensive and confident treatment planning.
Fill out a test request form in the Myriad Genetics provider portal
Our laboratory processing staff will contact your pathology partner directly to obtain the tumor sample for Precise Tumor testing
Results will be reported in the provider portal as they become available
With Myriad Oncology, you can receive comprehensive results for germline testing, tumor genomic profiling, and HRD testing in one single ordering experience, getting clear, fast answers for your patients.
For a complete approach to cancer risk management and treatment planning, Precise Tumor should be combined with MyRisk and appropriate tumor test to deliver powerful results informing patient care across the entire journey-from assessing hereditary cancer syndromes to guiding treatment decisions.
Combine germline and tumor genomic insights to identify hereditary cancer risks and actionable gene variants, enabling personalized treatment plans and targeted therapies. MyRisk and Precise Tumor focus on clinically relevant variations in the genome, where each test couples RNA analysis with DNA sequencing to provide more refined interpretation of results.
Integrate germline and tumor genomic profiling with HRD testing to identify more patients most likely to benefit from PARP inhibitors. Precise Tumor and MyChoice deliver a powerful combination of actionable tumor genomic information and homologous recombination status, optimizing treatment strategies for ovarian cancers.
For your patients with early-stage breast cancer, pair germline testing with tumor genomic insights and breast cancer recurrence assessment to guide personalized decisions on risk-reducing surgeries and adjuvant therapy strategies.
Precise Tumor simplifies patient care for oncologists by providing straightforward interpretations, prioritization of therapies, and the next steps specific to each patient’s genomic results.
Precise Tumor combines DNA and RNA sequencing to detect more fusions and splice variants compared to DNA-only tests.2-5 Precise Tumor is validated to 98.91% analytical sensitivity and >99.99% analytical specificity.1
Transparent pricing with personalized cost estimates, financial assistance, and other affordability options including direct pay.
Myriad Genetics, MyRisk, Precise Tumor, MyChoice, Prolaris, BRACAnalysis CDx, RiskScore, and their respective logos, are registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions. EndoPredict and the EndoPredict logo are either trademarks or registered trademarks of Eurobio Scientific.